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Results The overall response rate and the complete 
response (CR) rate were 100 and 43.8 %, respectively. 
In particular, one patient with CR and two patients with 
very good PR at enrollment achieved stringent CR dur-
ing 6 courses of sVRD. With a median follow-up time of 
29.4 months, the median progression-free survival (PFS) 
and overall survival (OS) were not reached, while the PFS 
and OS rates at 2.5 years were 66.6 and 77.3 %, respec-
tively. Univariate analysis demonstrated that disease pro-
gression as a reason for discontinuation of sVRD had a 
negative impact on OS. There were no grade 3 or 4 hemato-
logic or nonhematologic AEs.
Conclusion Our sVRD regimen as a consolidation/mainte-
nance therapy was highly effective and well tolerable.
Keywords Multiple myeloma · Consolidation/
maintenance · Bortezomib · Lenalidomide · 
Dexamethasone · VRD
Introduction
Over the past 10 years, the median overall survival (OS) 
of patients with multiple myeloma (MM) has considerably 
increased due to the use of autologous hematopoietic stem 
cell transplantation (HSCT) and the introduction of the 
immunomodulatory drugs, thalidomide and lenalidomide, 
and the proteasome inhibitor, bortezomib, in transplant-
eligible and transplant-ineligible patients [1].
In order to consolidate and maintain the outcome after 
induction therapy with these novel agents, consolidation/
maintenance therapy has been an attractive choice. Con-
solidation (two to four cycles of combination therapies) 
and maintenance (continuous therapy, usually with single 
agents, until the time of disease progression) are commonly 
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Purpose Consolidation/maintenance therapy induces deep 
remission in patients with multiple myeloma (MM); how-
ever, the most suitable regimen has been under investiga-
tion. The combination therapy with bortezomib, lenalido-
mide and dexamethasone (VRD) is a powerful regimen for 
relapsed/refractory as well as newly diagnosed MM as an 
induction therapy. However, severe adverse events (AEs) 
may become a problem when VRD is introduced without 
dose reduction as a consolidation/maintenance therapy.
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solidation/maintenance setting. Sixteen patients who had 
partial response (PR) or better after any induction therapy 
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used in clinical practice after induction therapy, although 
no specific guidelines are available [2].
There have been many trials to support the use of con-
solidation/maintenance to maintain the response achieved 
after autologous HSCT or conventional treatments and to 
improve patient survival with single agent or combination 
therapy: thalidomide [3–8], lenalidomide [9–12], borte-
zomib [13], bortezomib plus thalidomide [14, 15] and bort-
ezomib, thalidomide plus dexamethasone [16, 17]. How-
ever, no definitive information is available regarding which 
drug or which combination of drugs is the most favorable 
for consolidation/maintenance.
Concerning this matter, Kikuchi et al. [18] published 
an informative study using in vitro isobologram analysis. 
They demonstrated that lenalidomide has strong combined 
effects with bortezomib on myeloma cells in the presence 
of stromal cells. The bortezomib-induced up-regulation 
of CCAAT/enhancer-binding protein homologous protein 
(CHOP), a pro-apoptotic transcription factor, was readily 
enhanced by lenalidomide in contact with stromal cells. 
Their findings are compatible with the report that the over-
all response rate (ORR) (i.e., very good partial response 
or better) of the combination of bortezomib, lenalidomide 
and dexamethasone (VRD) was higher than those of bort-
ezomib, doxorubicin and dexamethasone (PAD), bort-
ezomib, thalidomide and dexamethasone (VTD), or cyclo-
phosphamide, bortezomib and dexamethasone (CVD) in 
newly diagnosed myeloma patients [19].
The combination regimen of VRD was first evaluated 
in patients with relapsed or relapsed/refractory MM in a 
phase I, dose-escalation study by Richardson et al. [20]. 
Then, they reported a phase II study to evaluate the efficacy 
and safety of VRD in the same relapsed or relapsed/refrac-
tory setting [21]. Also in a frontline setting, they reported 
favorable toxicity and promising response and survival of 
patients treated with the VRD regimen in a phase I/II study 
[22]. Some other reports confirmed the efficacy of the VRD 
regimen as a frontline [23] or second-line treatment [24, 
25].
Especially, Roussel et al. [23] evaluated the efficacy of 
three courses of the VRD regimen as an induction treat-
ment for previously untreated patients; their VRD regi-
men consisted of 3-week cycles of intravenous bortezomib 
1.3 mg/m2 on days 1, 4, 8 and 11; oral lenalidomide 25 mg 
on days 1 to 14; and oral dexamethasone 40 mg on days 1, 
8 and 15. They reported that the ORR at the completion of 
induction therapy was 58 %.
In consideration of this high efficacy, the combination of 
bortezomib, lenalidomide and dexamethasone is attractive 
for consolidation/maintenance treatment; however, adverse 
events (AEs) were not negligible with the full dosage of 
their VRD regimen. The most common toxicities with the 
VRD regimen were neurologic and hematologic, including 
grade 1–2 sensory neuropathy (55 %), grade 3–4 neutrope-
nia (35 %) and thrombocytopenia (13 %) [23].
Therefore, we conducted a phase II study reported 
herein evaluating the efficacy and safety of small-dose 
VRD (sVRD) in the consolidation/maintenance setting.
Methods
Study design and objective
The aim of this multicenter, open-label, single-arm, phase 
II study was to determine the efficacy and safety of sVRD 
in Japanese patients with MM in the consolidation/mainte-
nance setting. The primary end point of this study was the 
best ORR during 6 courses of sVRD. Secondary end points 
included progression-free survival (PFS), OS and safety. 
This study was conducted according to the Declaration 
of Helsinki and was approved by the institutional review 
board of each participating center. The institutional review 
board-approved consent form was signed by all patients 
before participating in this study. This trial is registered at 
www.umin.ac.jp (#UMIN8236).
Patients
Eligible patients were age ≥20 and ≤80 years, with meas-
urable symptomatic MM. Patients must have received 
at least 1 prior regimen and achieved at least a partial 
response (PR) by the International Myeloma Working 
Group (IMWG) Uniform Response Criteria. Other eligibil-
ity criteria included Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0–2, and an expected 
survival of more than 3 months. Adequate pulmonary, car-
diac, renal and hepatic functions were required.
Treatment
Patients received subcutaneous bortezomib (1.3 mg/m2 on 
days 1 and 15), oral lenalidomide (10 mg on days 1–21) 
and oral dexamethasone (40 mg on days 1, 8, 15 and 
22). The course was repeated every 4 weeks for 6 cycles. 
Patients with at least a PR at the end of cycle 6 could con-
tinue sVRD treatment. Patients discontinued therapy if they 
experienced progressive disease (PD) or unacceptable tox-
icity, if no more additional benefits could be expected or 
if the patient/investigator decided to discontinue therapy 
for any reason. Dose adjustments were permitted based on 
grade 3 or 4 AEs or based on an investigator’s decision; 
bortezomib could be reduced from 1.3 to 1.0 mg/m2, lena-
lidomide from 10 to 5 mg/day and dexamethasone from 
40 to 20 mg/day. If a similar severity of toxicity occurred 
at the reduced dose, study treatment was discontinued. 
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Antiviral prophylaxis, bisphosphonates, aspirin thrombo-
prophylaxis and erythropoietic agents were permitted dur-
ing the study. Granulocyte colony-stimulating factor was 
also allowed.
Assessment of efficacy
Response assessments were conducted before enrollment 
and after each course of sVRD treatment. The ORR was 
defined as the proportion of patients whose best overall 
response was either a stringent complete response (sCR), 
complete response (CR), very good PR (VGPR) or PR 
based on responses as assessed using IMWG Uniform 
Response Criteria. sCR, CR, VGPR and PR required two 
consecutive assessments made at any time before progres-
sion or initiation of any new therapy. Patients were fol-
lowed for disease progression and OS for up to 3 years 
after discontinuation or completion of therapy.
Assessment of safety
AEs were assessed at each visit and were graded accord-
ing to National Cancer Institute Common Terminology 
Criteria (NCI-CTC) for AEs (Version 4.0). Data were col-
lected until 30 days after the last dose of study drug, except 
for secondary primary malignancies (SPM) (which were 
assessed all along during follow-up). SPM was defined 
as any malignancy observed after introduction of sVRD 
treatment.
Statistical methods
The median follow-up time was estimated using the reverse 
Kaplan–Meier method. PFS was calculated as the time 
from the start of treatment to the first documentation of PD 
or death if the patient died as a result of any cause before 
progression. OS was calculated as the time from the start of 
treatment to death. The Kaplan–Meier method was used to 
estimate the survival distribution. Univariate survival anal-
ysis was performed using the Kaplan–Meier method. The 
significance of differences in survival curves was assessed 
with the log-rank test. Multivariable analysis (Cox propor-
tional hazards regression model) of OS was carried out on 
all covariates that showed a significant association with OS 
in univariate analysis. All analyses were conducted using 
GraphPad Prism version 5.0 (GraphPad Software, La Jolla, 
CA) and EZE (Saitama Medical Center, Jichi Medical Uni-
versity; http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/
statmedEN.html) [26].
Results
Patients and treatments
From June 2012 until November 2013, 16 MM patients 
were enrolled at 4 sites in Japan. The data cutoff date for 
this analysis was March 10, 2015. Patient demographics 
and baseline characteristics are summarized in Table 1. 
The median age was 67 years (range 53–78 years); 12 
patients (75.0 %) were >65 years. Eleven patients (68.8 %) 
were male. The median time from diagnosis to enrollment 
Table 1  Characteristics of the patients with MM who received the 
sVRD regimen
ISS International Staging System, D–S Durie and Salmon, HSCT 
hematopoietic stem cell transplantation
a Data were obtained by fluorescence in situ hybridization (FISH)
Characteristic All patients (n = 16)
Age [mean (range)] 67 (53–78)
Male sex [n (%)] 11 (68.8)
Mean time from diagnosis to enrollment 
[months (range)]
17 (4–95)
PS [n (%)]
 0 8 (50.0)
 1 6 (37.5)
 2 2 (12.5)
Type of myeloma [n (%)]
 IgG 10 (62.5)
 IgA 6 (37.5)
 Kappa 13 (81.3)
 Lambda 3 (18.7)
ISS stage at enrollment [n (%)]
 I 13 (81.3)
 II 3 (18.7)
 III 0 (0)
D–S stage at enrollment [n (%)]
 I 14 (87.5)
 II 0 (0)
 III 2 (12.5)
Cytogenetic abnormalitiesa [n (%)]
 del 17 1/11 (9.1)
 t(14;16) 0/7 (0)
 del 13 4/9 (44.4)
 t(4;14) 3/7 (42.9)
Induction regimen [n (%)]
 Any use of dexamethasone 14 (87.5)
 Any use of bortezomib 13 (81.3)
 Any use of lenalidomide 7 (43.8)
 Any use of doxorubicin 4 (25.0)
 Any use of melphalan 3 (18.8)
 Any use of cyclophosphamide 2 (12.5)
 Radiation 7 (43.8)
 HSCT 4 (25.0)
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was 17 months (range 4–95 months). ECOG PS was 0 
in 50.0 %, 1 in 37.5 % and 2 in 12.5 % of the patients. 
They had either IgG (62.5 %) or IgA (37.5 %) myeloma 
and had either Kappa (81.3 %) or Lambda (18.7 %) light 
chain. After restaging at the time of enrollment, 81.3 % of 
patients had stage I and 18.7 % stage II according to the 
classification system of the International Staging System 
(ISS), and 87.5 % had stage I and 12.5 % stage III accord-
ing to the system of Durie and Salmon (D-S). Fluores-
cence in situ hybridization (FISH) performed at the time 
of diagnosis showed that 1 (9.1 %) out of 11 patients had 
del 17, 4 (44.4 %) out of 9 del 13 and 3 (42.9 %) out of 
7 t(4;14). The induction therapies before enrollment in this 
study were as follows: 87.5 % of patients were treated with 
dexamethasone, 81.3 % bortezomib, 43.8 % lenalidomide, 
25.0 % doxorubicin, 18.8 % melphalan and 12.5 % cyclo-
phosphamide. 43.8 % of patients had undergone radiation 
therapy. 25.0 % of patients had undergone at least one 
HSCT.
Duration of treatment
All patients could complete 6 courses of sVRD treatment 
(Table 2). The median duration of sVRD treatment was 
8.0 courses (range 6–28 courses), with 56.3 % (n = 9) and 
25.0 % (n = 4) undergoing >6 and >12 cycles, respectively. 
At the data cutoff date, all 16 patients had discontinued 
treatment. The reasons for treatment discontinuation were 
completion of 6 courses (n = 7, 43.8 %), disease progres-
sion (n = 3, 18.8 %), SPM of acute lymphoblastic leukemia 
(ALL) (n = 1, 6.3 %), AE of grade 2 pneumonia (n = 1, 
6.3 %) or other (patient refusal or physician preference) 
(n = 4, 25.0 %).
Response
All 16 patients were response-evaluable. The ORR during 6 
courses of sVRD treatment is shown in Table 3. 43.8 % had 
an sCR, 0 % CR, 6.3 % VGPR, 50.0 % PR and 0 % PD. The 
ORR and CR rate (i.e., at least CR) were 100 and 43.8 %, 
respectively. In detail, at enrollment, 4 patients were deter-
mined to be in sCR, 1 in CR, 2 in VGPR and 9 in PR. Dur-
ing 6 courses of sVRD, 4 patients with sCR at enrollment 
remained in sCR. One patient with CR and 2 with VGPR 
achieved sCR. In 9 patients with PR, 1 achieved VGPR, but 
8 remained in PR. Nevertheless, 2 out of 8 patients with 
PR after 6 courses of sVRD finally achieved VGPR or sCR 
after a total of 18 or 24 courses of sVRD, respectively. Sta-
tus at enrollment of a patient with del(17p) was PR, and 
his best overall response was the same PR. Table 4 demon-
strates that all four patients (No. 5–8) who obtained deeper 
response during 6 courses of sVRD were treated without 
lenalidomide in induction therapies.
PFS and OS
With a median follow-up time of 29.4 months (range 16.1–
33.1 months), 13 out of 16 patients are still alive, 11 of 
whom are progression-free for a maximum of 33.1 months. 
Three patients died and their cause of death was disease 
progression in all cases. One of these three patients who 
died had SPM of myelodysplastic syndrome (MDS). One 
had chromosomal abnormality of del(17p). It is notewor-
thy that the three patients who discontinued sVRD treat-
ment due to PD were the same three patients who died in 
spite of various post-study therapies. Figure 1 shows the 
Kaplan–Meier estimates of PFS and OS. The median PFS 
was not reached, and the 2.5-year PFS was 66.6 % (95 % 
confidence interval [CI] 36.9–84.8 %). The median survival 
Table 2  Treatment duration of 
the sVRD regimen
All patients (n = 16)
Completion of 6 courses [n (%)] 16 (100)
Mean treatment duration [courses (range)] 8.0 (6–28)
Reason for discontinuation [n (%)]
 Completion of 6 courses 7 (43.8)
 Disease progression 3 (18.8)
 Second primary malignancy (acute lymphoblastic leukemia) 1 (6.3)
 Adverse events (pneumonia) 1 (6.3)
 Others 4 (25.0)
Table 3  Best overall response during 6 courses of sVRD
sCR stringent complete response, CR complete response, VGPR very 
good partial response, PR partial response, PD progressive disease
Status at enrollment Best overall response
sCR CR VGPR PR PD
sCR (n = 4) 4 0 0 0 0
CR (n = 1) 1 0 0 0 0
VGPR (n = 2) 2 0 0 0 0
PR (n = 9) 0 0 1 8 0
Total (n = 16) [n (%)] 7 (43.8) 0 (0) 1 (6.3) 8 (50.0) 0 (0)
1045Cancer Chemother Pharmacol (2016) 78:1041–1049 
1 3
time (MST) was also not reached, and the 2.5-year survival 
rate was 77.3 % (95 % CI 44.3–92.2 %).
Univariate analysis
When analyzing prognostic factors for OS, univariate 
analysis using the log-rank test confirmed well-known 
prognostic parameters such as PS (P = 0.00569), albu-
min (P = 0.0000323), ISS (P = 0.0123) and del 17 
(P = 0.00157) to be of prognostic relevance in our patient 
cohort (Table 5). Regarding best overall response during 
6 courses of sVRD, OS was negatively influenced by PR 
compared with sCR, CR or VGPR (P = 0.0334). Further-
more, disease progression as a reason for discontinuation 
of sVRD had a negative impact on OS in comparison with 
other reasons (P = 0.0000374). These results indicated that 
refractoriness to the sVRD regimen could not be easily res-
cued by any post-study therapies. Nevertheless, none of 
the variables selected on univariate analysis was an inde-
pendent prognostic marker for OS in the Cox proportional 
hazards regression model since the number of patients for 
multivariate analysis was small.
Safety
One dose modification of dexamethasone from 40 to 
20 mg/day was required because of grade 2 hypertension 
after the 3rd course of sVRD. One patient had discontinued 
Table 4  Best overall response and induction regime
Bor bortezomib, Len lenalidomide, Dex dexamethasone, Dox doxorubicin, Mel melphalan, CY cyclophosphamide, RT radiation, HSCT hemat-
opoietic stem cell transplantation
Patient no. Status at enrollment Best overall response Induction regimen
Bor Len Dex Dox Mel CY RT HSCT
1 sCR sCR ✓ ✓ ✓ ✓
2 sCR sCR ✓ ✓ ✓ ✓
3 sCR sCR ✓ ✓
4 sCR sCR ✓ ✓ ✓ ✓
5 CR sCR ✓ ✓
6 VGPR sCR ✓ ○ ✓ ✓
7 VGPR sCR ✓ ✓ ✓
8 PR VGPR ✓ ✓ ✓
9 PR PR ✓ ✓ ✓ ✓
10 PR PR ✓ ✓
11 PR PR ✓ ✓ ✓ ✓ ✓
12 PR PR ✓ ✓
13 PR PR ✓ ✓ ✓ ✓ ✓
14 PR PR ✓ ✓ ✓ ✓
15 PR PR ✓ ✓ ✓
16 PR PR ✓ ✓ ✓ ✓
Total (n = 16) 16 16 13 7 14 4 3 2 7 4
Fig. 1  Kaplan–Meier curves 
of PFS and OS of MM patients 
who received the sVRD regi-
men. a PFS (the median PFS 
was not reached). b OS (the 
median OS was not reached)
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all study drugs because of grade 2 pneumonia after 6 
courses of sVRD. AEs are summarized in Table 6. Grade 2 
sensory neuropathy was reported in two patients; however, 
neuropathy occurred in each patient during their induction 
therapies and lasted thereafter with no worsening. Grade 2 
neutropenia occurred in 2 patients, pneumonia in 2, throm-
bocytopenia in 1, hypertension in 1, constipation in 1 and 
anemia in 1. There were no grade 3 or 4 hematologic or 
nonhematologic AEs.
Secondary primary malignancies
After enrollment, 2 new hematologic malignancies, i.e., 
ALL in one patient and MDS in another patient, were diag-
nosed (Table 7). The time from diagnosis to enrollment was 
38 or 60 months in the patient with ALL or MDS, respec-
tively. The former patient was pretreated with vincristine, 
adriamycin and dexamethasone (VAD) and autologous 
HSCT (ASCT) and then underwent 18 courses of sVRD 
treatment. He discontinued sVRD due to the occurrence of 
ALL. He has been alive after the standard induction/con-
solidation chemotherapy for ALL and allogeneic HSCT. 
The latter patient was pretreated with VAD and bortezomib 
plus dexamethasone (Bd) and then underwent sVRD treat-
ment. After the 7th course, the sVRD regimen was stopped 
due to disease progression. The combination regimen of 
melphalan, prednisone and lenalidomide (MPR) was intro-
duced as a post-study therapy, and a gradual dose reduction 
of melphalan was needed because of progressive pancyto-
penia. The diagnosis of MDS was made based on the find-
ings of bone marrow aspiration. He finally died of PD.
Discussion
Three previous reports investigated the regimen of bort-
ezomib–lenalidomide–dexamethasone in the consolidation/
maintenance setting [21, 23, 27] (Table 8). In the report 
by Roussel et al. [23], previously untreated patients were 
treated with the VRD regimen, as an induction therapy for 
three cycles and a consolidation therapy for two cycles 
after ASCT. Nooka et al. [27] treated previously untreated 
patients with the VRD regimen as a maintenance therapy 
after ASCT for three years. Richardson et al. [21] admin-
istered the VRD regimen in relapsed/refractory patients, as 
a re-induction therapy for eight cycles and a maintenance 
Table 5  Univariate analysis (log-rank test) of prognostic factors for 
overall survival
Characteristic Number of cases P value
Sex
 Male 11 0.27
 Female 5
Age (year)
 >67 7 0.766
 ≤67 9
PS
 ≥2 2 0.00569
 <2 14
Beta-2 microglobulin (mg/L)
 ≥2.5 3 0.507
 <2.5 13
Albumin (g/dL)
 <3.5 2 0.0000323
 ≥3.5 14
ISS stage at enrollment
 II, III 3 0.0123
 I 13
del 13
 Yes 4 0.371
 No 5
4(4;14)
 Yes 3 0.386
 No 4
del 17
 Yes 1 0.00157
 No 10
Status at enrollment
 PR 9 0.0731
 sCR, CR, VGPR 7
Best overall response during 6 courses
 PR 8 0.0334
 sCR, CR, VGPR 8
Reason for discontinuation
 Disease progression 3 0.0000374
 Others 13
Second primary malignancy
 Yes 2 0.296
 No 14
Table 6  Adverse events
a Preexisting neuropathy with no worsening
Adverse events Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
Sensory neuropathy 2 (12.5)a 0 (0) 0 (0)
Neutropenia 2 (12.5) 0 (0) 0 (0)
Pneumonia 2 (12.5) 0 (0) 0 (0)
Thrombocytopenia 1 (6.3) 0 (0) 0 (0)
Hypertension 1 (6.3) 0 (0) 0 (0)
Constipation 1 (6.3) 0 (0) 0 (0)
Anemia 1 (6.3) 0 (0) 0 (0)
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therapy until PD. In our trial, patients with at least PR after 
any induction therapy were enrolled to receive our sVRD 
regimen as a consolidation/maintenance therapy for at least 
6 cycles.
Even though the same terminology of VRD was used in 
the three previous reports, the dosages of bortezomib and 
lenalidomide were not the same. On average, Roussel et al. 
[23], Nooka et al. [27] and Richardson et al. [21] adminis-
tered bortezomib at 1.7, 1.3 or 1.3 mg/m2/week and lena-
lidomide at 17, 7.5 or 10 mg/day, respectively. In our trial, 
bortezomib and lenalidomide were administered at 0.7 mg/
m2/week and 7.5 mg/day, respectively. The dosages of bort-
ezomib and lenalidomide used in our trial were the lowest 
compared with those reported by Roussel et al. [23], Nooka 
et al. [27] and Richardson et al. [21]. Improvement in toler-
ability and the preservation of efficacy compared with the 
three previous reports were important issues in our trial.
The most common toxicities related to the VRD regimen 
were neurologic and hematologic. Grade 1–2 peripheral 
neuropathy (PN) was reported in 55 or 53 % of patients 
by Roussel et al. [23] and Richardson et al. [21], respec-
tively. In our trial, two patients (13 %) experienced grade 
2 PN; however, their neuropathy was due to prior usage 
of bortezomib with no worsening after enrollment in our 
study. A lower occurrence of PN possibly reflects the lower 
dosage of bortezomib at 0.7 mg/m2/week. In addition, 
Table 7  Second primary 
malignancies (SPMs)
VAD vincristine, adriamycin and dexamethasone, ASCT autologous hematopoietic stem cell transplanta-
tion, Bd bortezomib plus dexamethasone
SPM n (%) Time to enrollment (months) sVRD (courses) Prior therapies
Acute lymphoblastic leukemia 1 (6.3) 38 18 VAD, ASCT
Myelodysplastic syndrome 1 (6.3) 60 7 VAD, Bd
Table 8  VRD regimens used for consolidation and/or maintenance
PD progressive disease, IV intravenous, SC subcutaneous, ASCT autologous hematopoietic stem cell transplantation, PR partial response, PN 
peripheral neuropathy, N.D. not described, NP neutropenia, TCP thrombocytopenia, ORR overall response rate, OS overall survival
a 6/36 patients had PN at baseline
b 2/2 patients had PN at baseline
Roussel et al. J Clin Oncol 
2014 (23)
Nooka et al. Leukemia 2014 
(27)
Richardson et al. Blood 2014 
(21)
Our trial
Patients Previously untreated Previously untreated (high-
risk)
Relapsed/
refractory
≥PR after any induction
Phases of treatment Induction
 3 cycles
Consolidation (after ASCT)
 2 cycles
Maintenance (after ASCT)
 3 years
Induction
 8 cycles
Maintenance
 until PD
Consolidation/maintenance
 ≥6 cycles
Cycle length 21 days 28 days 21 days 28 days
Bortezomib 1.3 mg/m2
IV
days 1, 4, 8, 11
1.3 mg/m2
IV or SC
days 1, 8, 15, 22
1.0 mg/m2
IV
days 1, 4, 8, 11
1.3 mg/m2
SC
days 1, 15
<Average> 1.7 mg/m2/week 1.3 mg/m2/week 1.3 mg/m2/week 0.7 mg/m2/week
Lenalidomide 25 mg/body
days 1–14
10 mg/body
days 1–21
15 mg/body
days 1–14
10 mg/body
days 1–21
<Average> 17 mg/day 7.5 mg/day 10 mg/day 7.5 mg/day
Dexamethasone 40 mg/body
days 1, 8, 15
40 mg/body
days 1, 8, 15, 22
40 mg/body
days 1, 2, 4, 5, 8, 9, 11, 12
(cycles 1–4)
40 mg/body
days 1, 8, 15, 22
<Average> 40 mg/week 40 mg/week 107 mg/week 40 mg/week
PN (G1–2) 55 % N.D. 53 %a 13 %b
NP (G3–4) 35 % N.D. 30 % 0 %
TCP (G3–4) 13 % N.D. 22 % 0 %
Dose modification 39 % 40 % 66 % 7 %
ORR 100 % 100 % 64 % 100 %
OS 100 % (3 years) 93 % (3 years) 65 % (2 years) 77 % (2.5 years)
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subcutaneous administration of bortezomib instead of intra-
venous injection may reduce the occurrence of PN since it 
is well known that PN of any grade was significantly less 
common with subcutaneous than with intravenous admin-
istration [28, 29]. As for hematologic toxicities, grade 
3–4 neutropenia (NP) (35 or 30 %) and thrombocytopenia 
(TCP) (13 or 22 %) were reported by Roussel et al. [23] 
and Richardson et al. [21], respectively. In our trial, there 
were no cases of grade 3–4 NP and TCP, possibly reflecting 
the lower dosage of lenalidomide at 7.5 mg/day on average.
Furthermore, the tolerability of each VRD regimen 
could be evaluated by the necessity of dose modification. 
In the reports by Roussel et al. [23], Nooka et al. [27] 
and Richardson et al. [21], at least one dose modification 
among bortezomib, lenalidomide and dexamethasone was 
required in 39, 40 or 66 % of patients, respectively. On the 
other hand, dose modification was required in only one 
patient (7 %) in our trial: The dose of dexamethasone was 
reduced from 40 to 20 mg/week due to grade 2 hyperten-
sion after the 3rd course of sVRD. Especially, in the report 
by Roussel et al. [23], patients were previously untreated 
and relatively young (range 33–65 years) compared with 
our patients (range 53–78 years); however, almost 40 % of 
patients could not complete five courses with their dosage 
of bortezomib (1.7 mg/m2/week) and lenalidomide (17 mg/
day). All of our patients could complete six courses of our 
sVRD regimen. Taking AEs and dose modification into 
consideration, the dosage of bortezomib (0.7 mg/m2/week) 
and lenalidomide (7.5 mg/day) in our trial might be well 
rationalized.
As for the efficacy of each VRD regimen, the ORR 
could be comparable. In the reports by Roussel et al. [23], 
Nooka et al. [27] and Richardson et al. [21], the ORR was 
100, 100 or 64 %, respectively. Further, OS was 100 % (3 
years), 93 % (3 years) or 65 % (2 years), respectively. The 
ORR and OS in the report by Richardson et al. [21] were 
lower than those in the reports by Roussel et al. [23] and 
Nooka et al. [27] since the patients in the study of Rich-
ardson et al. [21] were relapsed/refractory. In our trial, the 
ORR and OS were 100 and 77 % (2.5 years), respectively. 
Needless to say, it is difficult to precisely compare the 
ORR and OS of our trial with those of other three reports 
because of many biases. Nevertheless, it can be speculated 
that the low dosage of bortezomib and lenalidomide in our 
trial did not necessarily result in decreased efficacy. We 
conclude that the dosage of bortezomib and lenalidomide 
in our sVRD regimen may be able to reduce AEs and have 
preserved efficacy simultaneously in the consolidation/
maintenance setting.
In conclusion, our sVRD regimen as a consolidation/
maintenance therapy was well tolerable and highly effec-
tive in patients with MM who achieved at least PR after any 
induction therapy. These results seem comparable to those 
of the other VRD regimens previously published [21, 23, 
27] and hence support the rationale for our ongoing phase 
II study of the sVRD regimen in previously untreated trans-
plant-ineligible patients with MM.
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